Clarity’s COBRA study selected as a Top-Rated Oral Presentation at prestigious industry Annual Meeting
Sydney, Australia 1 October 2024 Highlights Two abstracts outlining Clarity’s latest SAR-bisPSMA data have been accepted to be presented at the upcoming European Association of Nuclear Medicine (EANM) 2024 Congress on the 19-23 October. Abstracts on the diagnostic clinical trial, COBRA, and a theranostic case report (complete response in a patient with metastatic castrate-resistant prostate…